• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

乳腺髓样癌再探讨。

Medullary cancer of the breast revisited.

作者信息

Fisher E R, Kenny J P, Sass R, Dimitrov N V, Siderits R H, Fisher B

机构信息

Institute of Pathology, Shadyside Hospital, Pittsburgh, PA 15232.

出版信息

Breast Cancer Res Treat. 1990 Oct;16(3):215-29. doi: 10.1007/BF01806330.

DOI:10.1007/BF01806330
PMID:2085673
Abstract

Common as well as unusual, heretofore unmentioned histopathologic features observed in 336 typical and 273 atypical medullary breast cancers from 6404 patients enrolled in various stage I and II protocols of the National Surgical Adjuvant Breast and Bowel Projects (NSABP) are presented. Both medullary types exhibited comparable pathologic findings, except for the infiltrative border and/or slight or absent tumor lymphoid infiltrate which by definition characterize the atypical form. Both also demonstrated a similar, high proclivity to be aneuploid, and to lack estrogen and progesterone receptors and nodal metastases. After appropriate statistical adjustments, survival (analyzed for 198 patients with typical and 149 with atypical medullary cancers) was found to be better for untreated, node-negative and node-positive patients treated with L-PAM + 5Fu who had typical medullary cancers than those with the NOS histologic type. The magnitude of this difference was 6% at 5 and 17% at 10 years post-operatively (cumulative odds = 1.81 with a 95% confidence interval of 1.08 - 3.3) for the former group, and 4% at 5 and 16% at 10 years (cumulative odds = 1.56 with a 95% confidence interval of 1.08 - 2.23) for the latter. Survival was comparable for patients with atypical medullary and NOS types in both situations. No clear difference in survival was found in untreated, positive node patients with the 3 histologic types examined, although the sample sizes in this subset were relatively small. This information as well as other pertinent considerations indicate that the prognosis of typical medullary cancer is not as 'good' as previously perceived. It is also concluded that there is insufficient evidence at present to exclude the atypical medullary variant as a histologic type of breast cancer.

摘要

本文呈现了在参与国家外科辅助乳腺和肠道项目(NSABP)不同I期和II期方案的6404例患者的336例典型和273例非典型髓样乳腺癌中观察到的常见以及不寻常的、此前未提及的组织病理学特征。除了浸润性边界和/或轻微或无肿瘤淋巴细胞浸润(根据定义这是不典型形式的特征)外,两种髓样类型表现出可比的病理结果。两者还都表现出相似的、高度的非整倍体倾向,缺乏雌激素和孕激素受体以及无淋巴结转移。经过适当的统计调整后,发现对于接受L-PAM + 5Fu治疗的未治疗、淋巴结阴性和淋巴结阳性的典型髓样癌患者,其生存率优于具有NOS组织学类型的患者。前一组在术后5年时差异幅度为6%,10年时为17%(累积优势比 = 1.81,95%置信区间为1.08 - 3.3),后一组在术后5年时为4%,10年时为16%(累积优势比 = 1.56,95%置信区间为1.08 - 2.23)。在两种情况下,非典型髓样癌和NOS类型患者的生存率相当。在所检查的3种组织学类型的未治疗、淋巴结阳性患者中未发现明显的生存差异,尽管该亚组中的样本量相对较小。这些信息以及其他相关因素表明,典型髓样癌的预后并不像先前认为的那么“好”。还得出结论,目前没有足够的证据将非典型髓样变体排除在乳腺癌的组织学类型之外。

相似文献

1
Medullary cancer of the breast revisited.乳腺髓样癌再探讨。
Breast Cancer Res Treat. 1990 Oct;16(3):215-29. doi: 10.1007/BF01806330.
2
Pathologic findings from the National Surgical Adjuvant Breast and Bowel Projects (NSABP). Prognostic discriminants for 8-year survival for node-negative invasive breast cancer patients.国家乳腺与肠道外科辅助治疗项目(NSABP)的病理研究结果。淋巴结阴性浸润性乳腺癌患者8年生存率的预后判别因素。
Cancer. 1990 May 1;65(9 Suppl):2121-8. doi: 10.1002/1097-0142(19900501)65:9+<2121::aid-cncr2820651408>3.0.co;2-m.
3
Prognostic factors in NSABP studies of women with node-negative breast cancer. National Surgical Adjuvant Breast and Bowel Project.NSABP关于淋巴结阴性乳腺癌女性患者研究中的预后因素。国家外科辅助乳腺和肠道项目。
J Natl Cancer Inst Monogr. 1992(11):151-8.
4
The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years.对于淋巴结阴性乳腺癌患者,p53和c-erb B-2免疫染色的预后价值被高估:对613例患者进行14至30年随访的预后因素多变量分析
Cancer. 2000 Feb 15;88(4):804-13. doi: 10.1002/(sici)1097-0142(20000215)88:4<804::aid-cncr11>3.0.co;2-y.
5
Alterations in hormonal receptor expression and HER2 status between primary breast tumors and paired nodal metastases: discordance rates and prognosis.原发性乳腺肿瘤与配对的淋巴结转移灶之间激素受体表达及HER2状态的改变:不一致率与预后
Asian Pac J Cancer Prev. 2014;15(21):9233-9. doi: 10.7314/apjcp.2014.15.21.9233.
6
S-phase fraction and nuclear size in long term prognosis of patients with breast cancer.乳腺癌患者长期预后中的S期分数与细胞核大小
Cancer. 1994 Oct 15;74(8):2287-99. doi: 10.1002/1097-0142(19941015)74:8<2287::aid-cncr2820740813>3.0.co;2-y.
7
Medullary carcinoma of the breast: ten year clinical experience of the Kuwait cancer control centre.乳腺髓样癌:科威特癌症控制中心的十年临床经验
Gulf J Oncolog. 2011 Jul(10):45-52.
8
Occult breast carcinoma presenting with axillary lymph node metastases: a follow-up study of 48 patients.以腋窝淋巴结转移为表现的隐匿性乳腺癌:48例患者的随访研究
Hum Pathol. 1990 May;21(5):518-23. doi: 10.1016/0046-8177(90)90008-s.
9
Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.通过联合评估p53和前列腺特异性抗原的表达增强乳腺癌预后预测
Br J Cancer. 1999 Oct;81(3):490-5. doi: 10.1038/sj.bjc.6690720.
10
Pathologic findings from the national surgical adjuvant breast project. Correlations with concordant and discordant estrogen and progesterone receptors.国家乳腺癌手术辅助项目的病理研究结果。与雌激素和孕激素受体一致及不一致情况的相关性。
Cancer. 1987 May 1;59(9):1554-9. doi: 10.1002/1097-0142(19870501)59:9<1554::aid-cncr2820590904>3.0.co;2-b.

引用本文的文献

1
Competing Risk Analyses of Medullary Carcinoma of Breast in Comparison to Infiltrating Ductal Carcinoma.比较乳腺髓样癌与浸润性导管癌的竞争风险分析。
Sci Rep. 2020 Jan 17;10(1):560. doi: 10.1038/s41598-019-57168-2.
2
Medullary Breast Carcinoma and Invasive Ductal Carcinoma: A Review Study.髓样乳腺癌和浸润性导管癌:一项综述研究
Iran J Med Sci. 2018 Jul;43(4):365-371.
3
Amplification of Genomic DNA for Decoy Receptor 3 Predicts Post-Resection Disease Recurrence in Breast Cancer Patients.诱饵受体3基因组DNA的扩增可预测乳腺癌患者术后疾病复发。

本文引用的文献

1
A histologic classification of carcinoma of the breast.乳腺癌的组织学分类。
Surgery. 1946 Jan;19:74-99.
2
The relatively favorable prognosis of medullary carcinoma of the breast.乳腺髓样癌相对较好的预后。
Cancer. 1949 Jul;2(4):635-42. doi: 10.1002/1097-0142(194907)2:4<635::aid-cncr2820020411>3.0.co;2-q.
3
Statistical aspects of the analysis of data from retrospective studies of disease.疾病回顾性研究数据的统计分析方面
World J Oncol. 2014 Feb;5(1):14-23. doi: 10.14740/wjon764w. Epub 2014 Mar 11.
4
Difference in characteristics and outcomes between medullary breast carcinoma and invasive ductal carcinoma: a population based study from SEER 18 database.髓样乳腺癌与浸润性导管癌的特征及预后差异:一项基于SEER 18数据库的人群研究
Oncotarget. 2016 Apr 19;7(16):22665-73. doi: 10.18632/oncotarget.8142.
5
Comparison of the characteristics of medullary breast carcinoma and invasive ductal carcinoma.比较髓样乳腺癌和浸润性导管癌的特征。
J Breast Cancer. 2013 Dec;16(4):417-25. doi: 10.4048/jbc.2013.16.4.417. Epub 2013 Dec 31.
6
Clinicopathologic characteristics at diagnosis and the survival of patients with medullary breast carcinoma in China: a comparison with infiltrating ductal carcinoma-not otherwise specified.中国髓样乳腺癌患者诊断时的临床病理特征与生存情况:与非特殊性浸润性导管癌的比较。
World J Surg Oncol. 2013 Apr 22;11:91. doi: 10.1186/1477-7819-11-91.
7
Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials.髓样乳腺癌的预后:13 项国际乳腺癌研究组(IBCSG)试验分析。
Ann Oncol. 2012 Nov;23(11):2843-2851. doi: 10.1093/annonc/mds105. Epub 2012 Jun 14.
8
A methyl-deviator epigenotype of estrogen receptor-positive breast carcinoma is associated with malignant biology.雌激素受体阳性乳腺癌的甲基化偏离表型与恶性生物学相关。
Am J Pathol. 2011 Jul;179(1):55-65. doi: 10.1016/j.ajpath.2011.03.022. Epub 2011 May 13.
9
Management of Rare Histological Types of Breast Tumours.罕见组织学类型乳腺肿瘤的管理
Breast Care (Basel). 2008;3(3):190-196. doi: 10.1159/000136826. Epub 2008 Jun 19.
10
Medullary carcinoma of the breast: a population-based perspective.乳腺髓样癌:基于人群的视角。
Med Oncol. 2011 Sep;28(3):738-44. doi: 10.1007/s12032-010-9526-z.
J Natl Cancer Inst. 1959 Apr;22(4):719-48.
4
Maximum utilization of the life table method in analyzing survival.在分析生存情况时最大限度地利用生命表法。
J Chronic Dis. 1958 Dec;8(6):699-712. doi: 10.1016/0021-9681(58)90126-7.
5
Medullary carcinoma of the breast; a distinctive tumour type with a relatively good prognosis following radical mastectomy.乳腺髓样癌;一种独特的肿瘤类型,根治性乳房切除术后预后相对较好。
Br J Cancer. 1956 Sep;10(3):415-23. doi: 10.1038/bjc.1956.48.
6
Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol no. 4). VI. Discriminants for five-year treatment failure.国家乳腺癌手术辅助治疗项目(协议号4)的病理研究结果。VI. 五年治疗失败的判别因素。
Cancer. 1980 Aug 15;46(4 Suppl):908-18. doi: 10.1002/1097-0142(19800815)46:4+<908::aid-cncr2820461310>3.0.co;2-5.
7
Pathologic findings from the National Surgical Adjuvant Project for Breast Cancers (protocol no. 4). X. Discriminants for tenth year treatment failure.国家乳腺癌手术辅助项目(方案编号4)的病理研究结果。X. 十年治疗失败的判别因素。
Cancer. 1984 Feb 1;53(3 Suppl):712-23. doi: 10.1002/1097-0142(19840201)53:3+<712::aid-cncr2820531320>3.0.co;2-i.
8
The significance of lymph node involvement in patients with medullary carcinoma of the breast.
Surg Gynecol Obstet. 1983 Dec;157(6):497-9.
9
Solid circumscribed carcinoma of the breast.乳腺实性局限性癌
Ann Surg. 1969 Feb;169(2):165-73. doi: 10.1097/00000658-196902000-00002.
10
Host resistance and survival in carcinoma of breast: a study of 104 cases of medullary carcinoma in a series of 1,411 cases of breast cancer followed for 20 years.乳腺癌患者的宿主抵抗力与生存率:对1411例乳腺癌患者中的104例髓样癌患者进行了为期20年的随访研究。
Br Med J. 1970 Jul 25;3(5716):181-8. doi: 10.1136/bmj.3.5716.181.